Cargando…

Comparison of cycle threshold values of the Cobas HPV test and viral loads of the BMRT HPV test in cervical cancer screening

OBJECTIVE: To validate the HPV viral loads that are reflected by the cycle threshold values of Cobas4800 as the viral load indicators by verifying the consistency of the viral loads per unit (10,000 cells) from the BMRT assay. METHODS: The analysis is based on data from the Chinese Multi-Center Scre...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Qing, Du, Hui, Qu, Xinfeng, Dai, Wenkui, Gui, Liming, Li, Changzhong, Wang, Chun, Guo, Chunlei, Zhang, Yi, Wei, Lihui, Belinson, J. L., Wu, Ruifang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686283/
https://www.ncbi.nlm.nih.gov/pubmed/36438219
http://dx.doi.org/10.3389/fpubh.2022.1010066
_version_ 1784835709805264896
author Yang, Qing
Du, Hui
Qu, Xinfeng
Dai, Wenkui
Gui, Liming
Li, Changzhong
Wang, Chun
Guo, Chunlei
Zhang, Yi
Wei, Lihui
Belinson, J. L.
Wu, Ruifang
author_facet Yang, Qing
Du, Hui
Qu, Xinfeng
Dai, Wenkui
Gui, Liming
Li, Changzhong
Wang, Chun
Guo, Chunlei
Zhang, Yi
Wei, Lihui
Belinson, J. L.
Wu, Ruifang
author_sort Yang, Qing
collection PubMed
description OBJECTIVE: To validate the HPV viral loads that are reflected by the cycle threshold values of Cobas4800 as the viral load indicators by verifying the consistency of the viral loads per unit (10,000 cells) from the BMRT assay. METHODS: The analysis is based on data from the Chinese Multi-Center Screening Trial (CHIMUST). The cases included in the analysis are all positive for physician-collected hrHPV on SeqHPV and/or Cobas4800 or negative for hrHPV but abnormal in cytology (≥LSIL), and some cases selected by nested case-control randomization from those negative for physician-collected hrHPV and cytology. With HPV testing results and relevant Ct values from Cobas4800 available, we tested the entire sample set with the BMRT HPV testing assay and analyzed their agreement with Cobas4800, followed by a comparison of the CtV from Cobas4800 and viral loads (lg) from BMRT by lesion grade. RESULTS: We included 4,485 women (mean age: 45.4 years) in the study, and 4,290 had complete data. The consistency of genotypes from Cobas4800 and BMRT for hrHPV, HPV-16, HPV-18, and 12-HPV pools was 94.9% (4070/4290, Kappa = 0.827), 99.1% (4251/4290, Kappa = 0.842), 99.6% (4,273/4,290, Kappa = 0.777), and 95.3% (4,089/4,290, Kappa = 0.821), respectively. Further analysis shows that any inconsistency between the two assays is likely among samples with comparatively lower viral loads. When analyzing per lesions of CIN2+ and CIN3+, the CtV from Cobas4800 and VL (lg) from BMRT are highly correlated inversely and follow the linear regression for HPV16 and 12-HPV pool (Pearson's or Spearman's correlation coefficient (r): In CIN3+, r (HPV16) = −0.641, P < 0.001; r (12−HPVpool) = −0.343, P = 0.109; In CIN2+, r (HPV16) = −0.754, P < 0.001; r (12−HPVpool) = −0.429, P < 0.001). CONCLUSION: The CtV from Cobas4800 and the viral loads (lg) of per unit cells from the BMRT are well correlated for lesion grading when tested on physician-collected samples. Cobas-CtV is worthy of further study for clinical application.
format Online
Article
Text
id pubmed-9686283
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96862832022-11-25 Comparison of cycle threshold values of the Cobas HPV test and viral loads of the BMRT HPV test in cervical cancer screening Yang, Qing Du, Hui Qu, Xinfeng Dai, Wenkui Gui, Liming Li, Changzhong Wang, Chun Guo, Chunlei Zhang, Yi Wei, Lihui Belinson, J. L. Wu, Ruifang Front Public Health Public Health OBJECTIVE: To validate the HPV viral loads that are reflected by the cycle threshold values of Cobas4800 as the viral load indicators by verifying the consistency of the viral loads per unit (10,000 cells) from the BMRT assay. METHODS: The analysis is based on data from the Chinese Multi-Center Screening Trial (CHIMUST). The cases included in the analysis are all positive for physician-collected hrHPV on SeqHPV and/or Cobas4800 or negative for hrHPV but abnormal in cytology (≥LSIL), and some cases selected by nested case-control randomization from those negative for physician-collected hrHPV and cytology. With HPV testing results and relevant Ct values from Cobas4800 available, we tested the entire sample set with the BMRT HPV testing assay and analyzed their agreement with Cobas4800, followed by a comparison of the CtV from Cobas4800 and viral loads (lg) from BMRT by lesion grade. RESULTS: We included 4,485 women (mean age: 45.4 years) in the study, and 4,290 had complete data. The consistency of genotypes from Cobas4800 and BMRT for hrHPV, HPV-16, HPV-18, and 12-HPV pools was 94.9% (4070/4290, Kappa = 0.827), 99.1% (4251/4290, Kappa = 0.842), 99.6% (4,273/4,290, Kappa = 0.777), and 95.3% (4,089/4,290, Kappa = 0.821), respectively. Further analysis shows that any inconsistency between the two assays is likely among samples with comparatively lower viral loads. When analyzing per lesions of CIN2+ and CIN3+, the CtV from Cobas4800 and VL (lg) from BMRT are highly correlated inversely and follow the linear regression for HPV16 and 12-HPV pool (Pearson's or Spearman's correlation coefficient (r): In CIN3+, r (HPV16) = −0.641, P < 0.001; r (12−HPVpool) = −0.343, P = 0.109; In CIN2+, r (HPV16) = −0.754, P < 0.001; r (12−HPVpool) = −0.429, P < 0.001). CONCLUSION: The CtV from Cobas4800 and the viral loads (lg) of per unit cells from the BMRT are well correlated for lesion grading when tested on physician-collected samples. Cobas-CtV is worthy of further study for clinical application. Frontiers Media S.A. 2022-11-10 /pmc/articles/PMC9686283/ /pubmed/36438219 http://dx.doi.org/10.3389/fpubh.2022.1010066 Text en Copyright © 2022 Yang, Du, Qu, Dai, Gui, Li, Wang, Guo, Zhang, Wei, Belinson and Wu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Yang, Qing
Du, Hui
Qu, Xinfeng
Dai, Wenkui
Gui, Liming
Li, Changzhong
Wang, Chun
Guo, Chunlei
Zhang, Yi
Wei, Lihui
Belinson, J. L.
Wu, Ruifang
Comparison of cycle threshold values of the Cobas HPV test and viral loads of the BMRT HPV test in cervical cancer screening
title Comparison of cycle threshold values of the Cobas HPV test and viral loads of the BMRT HPV test in cervical cancer screening
title_full Comparison of cycle threshold values of the Cobas HPV test and viral loads of the BMRT HPV test in cervical cancer screening
title_fullStr Comparison of cycle threshold values of the Cobas HPV test and viral loads of the BMRT HPV test in cervical cancer screening
title_full_unstemmed Comparison of cycle threshold values of the Cobas HPV test and viral loads of the BMRT HPV test in cervical cancer screening
title_short Comparison of cycle threshold values of the Cobas HPV test and viral loads of the BMRT HPV test in cervical cancer screening
title_sort comparison of cycle threshold values of the cobas hpv test and viral loads of the bmrt hpv test in cervical cancer screening
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686283/
https://www.ncbi.nlm.nih.gov/pubmed/36438219
http://dx.doi.org/10.3389/fpubh.2022.1010066
work_keys_str_mv AT yangqing comparisonofcyclethresholdvaluesofthecobashpvtestandviralloadsofthebmrthpvtestincervicalcancerscreening
AT duhui comparisonofcyclethresholdvaluesofthecobashpvtestandviralloadsofthebmrthpvtestincervicalcancerscreening
AT quxinfeng comparisonofcyclethresholdvaluesofthecobashpvtestandviralloadsofthebmrthpvtestincervicalcancerscreening
AT daiwenkui comparisonofcyclethresholdvaluesofthecobashpvtestandviralloadsofthebmrthpvtestincervicalcancerscreening
AT guiliming comparisonofcyclethresholdvaluesofthecobashpvtestandviralloadsofthebmrthpvtestincervicalcancerscreening
AT lichangzhong comparisonofcyclethresholdvaluesofthecobashpvtestandviralloadsofthebmrthpvtestincervicalcancerscreening
AT wangchun comparisonofcyclethresholdvaluesofthecobashpvtestandviralloadsofthebmrthpvtestincervicalcancerscreening
AT guochunlei comparisonofcyclethresholdvaluesofthecobashpvtestandviralloadsofthebmrthpvtestincervicalcancerscreening
AT zhangyi comparisonofcyclethresholdvaluesofthecobashpvtestandviralloadsofthebmrthpvtestincervicalcancerscreening
AT weilihui comparisonofcyclethresholdvaluesofthecobashpvtestandviralloadsofthebmrthpvtestincervicalcancerscreening
AT belinsonjl comparisonofcyclethresholdvaluesofthecobashpvtestandviralloadsofthebmrthpvtestincervicalcancerscreening
AT wuruifang comparisonofcyclethresholdvaluesofthecobashpvtestandviralloadsofthebmrthpvtestincervicalcancerscreening